Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Background: Semaglutide, a newly once-weekly glucagon like peptide-1 (GLP-1) receptor agonist, has showed a favorable effect on glycaemic control and weight reduction in type 2 diabetes mellitus (T2DM). This meta-analysis was conducted to evaluate the clinical efficacy and safety of semaglutide in T...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Fang-Hong, Li, Hao, Cui, Min, Zhang, Zai-Li, Gu, Zhi-Chun, Liu, Xiao-Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994433/
https://www.ncbi.nlm.nih.gov/pubmed/29915538
http://dx.doi.org/10.3389/fphar.2018.00576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994433/
https://www.ncbi.nlm.nih.gov/pubmed/29915538
http://dx.doi.org/10.3389/fphar.2018.00576

Ejemplares similares